The IBD SmartSelect Composite Rating for Krystal Biotech rose from 94 to 98 Friday.
The revised score means the stock currently tops 98% of all other stocks in terms of key performance metrics and technical strength. History shows the top market performers tend to have a 95 or higher score as they launch their major moves.
Krystal Biotech is not currently near a proper buy zone. See if the stock goes on to form a new base and offer a new buying opportunity.
Discover The 3 Keys To Successful Stock Investing
The stock sports an 82 EPS Rating, meaning its recent quarterly and annual earnings growth is outpacing 82% of all stocks.
Its Accumulation/Distribution Rating of B shows moderate buying by institutional investors over the last 13 weeks.
In Q4, the company posted 407% EPS growth. Top line growth fell to 116%, down from 879% in the previous quarter.
Krystal Biotech earns the No. 4 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics is the top-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
